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Summary
MicroRNAs (miRNAs) are regulatory RNAs found in
multicellular eukaryotes, including humans, where
they are implicated in cancer. The let-7 miRNA times
seam cell terminal differentiation in C. elegans. Here
we show that the let-7 family negatively regulates let-
60/RAS. Loss of let-60/RAS suppresses let-7, and the
let-60/RAS 3UTR contains multiple let-7 complemen-
tary sites (LCSs), restricting reporter gene expression
in a let-7-dependent manner. mir-84, a let-7 family
member, is largely absent in vulval precursor cell
P6.p at the time that let-60/RAS specifies the 1° vulval
fate in that cell, and mir-84 overexpression sup-
presses the multivulva phenotype of activating let-60/
RAS mutations. The 3UTRs of the human RAS genes
contain multiple LCSs, allowing let-7 to regulate RAS
expression. let-7 expression is lower in lung tumors
than in normal lung tissue, while RAS protein is sig-
nificantly higher in lung tumors, providing a possible
mechanism for let-7 in cancer.
Introduction
Hundreds of noncoding, regulatory RNAs known as
miRNAs (Bartel, 2004), are encoded in animal and plant
genomes (Lagos-Quintana et al., 2001; Lau et al., 2001;
Lee and Ambros, 2001). miRNAs have emerged as im-
portant regulators of development and control pro-
cesses such as cell fate determination and cell death
(Abrahante et al., 2003; Brennecke et al., 2003; Chang
et al., 2004; Chen et al., 2004; Johnston and Hobert,
2003; Lee et al., 1993; Lin et al., 2003; Moss et al., 1997;
Reinhart et al., 2000; Slack et al., 2000; Wightman et
al., 1993). Mounting evidence shows that miRNAs are
mutated or poorly expressed in human cancer (Calin et
al., 2002; Gauwerky et al., 1989; Lagos-Quintana et al.,
2002; McManus, 2003; Michael et al., 2003; Takami-
zawa et al., 2004; Tam, 2001; Tam et al., 2002), suggest-
ing that miRNAs may act as tumor suppressors or on-
cogenes. In animals, miRNAs usually control gene*Correspondence: frank.slack@yale.eduexpression through complementary elements in the 3#
untranslated regions (UTRs) of their target messenger
RNAs (mRNAs) (Lee et al., 1993; Moss et al., 1997;
Reinhart et al., 2000; Slack et al., 2000; Vella et al., 2004;
Wightman et al., 1993). However, the targets of few
mammalian miRNAs are known.
lethal-7 (let-7), a founding member of the miRNA fam-
ily, is required for timing of cell fate determination in
C. elegans (Pasquinelli et al., 2000; Reinhart et al.,
2000). In wild-type animals, temporal upregulation of
let-7 miRNA in the seam cells (Johnson et al., 2003;
Reinhart et al., 2000) is required for their terminal differ-
entiation at the adult stage (Reinhart et al., 2000) when
these cells exit the cell cycle, fuse together, and excrete
cuticular alae (Sulston and Horvitz, 1977). In let-7 mu-
tants, seam cells fail to exit the cell cycle and terminally
differentiate at the correct time and instead divide
(Reinhart et al., 2000), a hallmark of cancer. let-7 is con-
served in many phyla and, like in C. elegans, is tempo-
rally regulated in Drosophila and zebrafish (Pasquinelli
et al., 2000). In humans, various let-7 genes have been
reported to map to regions deleted in human cancers
(Calin et al., 2004), and let-7 is poorly expressed in lung
cancers (Takamizawa et al., 2004), suggesting that let-7
miRNAs may be tumor suppressors. In support of this,
overexpression of let-7 inhibited cell growth of a lung
cancer cell line in vitro (Takamizawa et al., 2004). How-
ever, the mechanism by which let-7 regulates cell cycle
exit in C. elegans and human cells is unknown.
C. elegans let-7, mir-48, mir-84, and mir-241 encode
four developmentally regulated miRNAs that comprise
the let-7 family (Lau et al., 2001; Lim et al., 2003; Rein-
hart et al., 2000). This family displays high sequence
identity, with particular conservation at the 5# end of
the mature miRNAs (see Figures S1A and S1B in the
Supplemental Data available with this article online).
The functions of these family members are unknown. In
this paper, we show a role for one of the C. elegans
let-7 family miRNAs, mir-84, in vulval development, a
model for dissecting RAS/MAP kinase signaling (Wang
and Sternberg, 2001). We also show that C. elegans let-
60/RAS is regulated by members of the let-7 family.
let-7 and mir-84 are complementary to multiple sites in
the 3#UTR of let-60/RAS. let-7 and mir-84 are ex-
pressed in a reciprocal manner to let-60/RAS in the hy-
podermis and the vulva, respectively. let-7 and mir-84
genetically interact with let-60/RAS, consistent with
negative regulation of RAS expression by let-7 and
mir-84. Our results also demonstrate that miRNAs regu-
late human RAS, a critical oncogene. We find that all
three human RAS genes have let-7 complementary
sites in their 3#UTRs that subject the oncogenes to
let-7 miRNA-mediated regulation in cell culture. Lung
tumor tissues display significantly reduced levels of
let-7 and significantly increased levels of RAS protein
relative to normal lung tissue, suggesting let-7 regula-
tion of RAS as a mechanism for let-7 in lung onco-
genesis.
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n
let-60/RAS as a Target of the let-7 miRNA
in C. elegans s
WThe let-7 miRNA is temporally expressed in C. elegans
(Johnson et al., 2003; Pasquinelli et al., 2000; Reinhart l
1et al., 2000) where it downregulates at least two target
genes, lin-41 (Slack et al., 2000) and hbl-1 (Abrahante a
2et al., 2003; Lin et al., 2003), mutations in which lead
to precocious terminal differentiation of seam cells. To t
sbetter understand the role of let-7 in C. elegans seam
cell differentiation and its potential role in humans, we 3
esought to identify additional targets of let-7. We per-
formed a computational screen for C. elegans genes m
twith let-7 family complementary sites (LCS) in their
3#UTR (Grosshans et al., 2005). One of the top-scoring t
7genes was let-60, encoding the C. elegans ortholog of
the human oncogene RAS. We identified eight LCSs in e
uthe 3#UTR of let-60 with features resembling validated
LCSs (Lin et al., 2003; Reinhart et al., 2000; Slack et al., e
32000; Vella et al., 2004; Figure 1A). Many of the iden-
tified sites were found in the 3#UTR of let-60 from the l
rclosely related nematode C. briggsae (Stein et al., 2003;
Figures 1A, S2A, and S2B), suggesting that they are f
llikely to be biologically significant. An additional three
sites were found in the let-60/RAS coding sequence as
well as 10 other nonconforming 3#UTR sites that may T
also bind to let-7 family miRNAs (Figure S2A). E
let-7(n2853ts) loss-of-function (lf) mutants express l
reduced let-7 miRNA and die by bursting at the vulva v
at the nonpermissive temperature (Reinhart et al., 2000; h
Slack et al., 2000). Lf mutations in two previously iden- C
tified targets of let-7, lin-41, and hbl-1 have the prop- t
erty of partially suppressing the let-7 lethal phenotype h
(Abrahante et al., 2003; Lin et al., 2003; Reinhart et al., w
2000; Slack et al., 2000). We found that postembryonic c
reduction of function of let-60 by feeding RNA interfer- p
ence (RNAi) also partially suppressed let-7(n2853) in a l
reproducible manner. While 5% of let-7 mutants grown e
on control RNAi survived at the nonpermissive temper- b
ature of 25°C (n = 302), 27% of let-7(n2853); let- m
60(RNAi) animals survived (n = 345) (Figures 2A and t
2B). Thus, similar to other known let-7 targets, let-60 lf w
partially suppresses the let-7(n2853) lethal phenotype, 1
suggesting that let-7 lethality may at least partially be i
caused by overexpression of let-60. However let- d
60(RNAi) did not appear to suppress the let-7 seam cell s
terminal differentiation defect and did not cause preco- h
cious seam cell terminal differentiation (data not l
shown). In addition, wild-type animals subjected to let- o
60(RNAi) did not display typical lethal and vulvaless t
phenotypes associated with let-60 alleles (Beitel et al., c
1990; Han et al., 1990; Han and Sternberg, 1990). Under s
our conditions, let-60(RNAi) resulted in w80% knock- t
down of let-60mRNA (Grosshans et al., 2005), suggest- p
ing that the remaining let-60 is still sufficient for seam S
cell differentiation and vulval development. To verify the w
specificity of the let-60(RNAi), we showed that while 1
let-7(mn112) adults all die, let-60(n2021); let-7(mn112) P
adults can live (see Experimental Procedures). Interest- f
ingly, let-7(n2853); let-60(RNAi) animals delivered a e
ibrood and could lay some eggs (data not shown), sug-esting that the vulval-bursting phenotype of let-7 was
ot suppressed merely because of the lack of a vulva.
let-60 and let-7 are both expressed in hypodermal
eam cells (Dent and Han, 1998; Johnson et al., 2003).
e fused the let-60 3#UTR behind the Escherichia coli
acZ gene driven by the hypodermally expressing col-
0 promoter (Figure 2C). We found that reporter gene
ctivity is downregulated around the L4 stage (Figures
D–2F), around the same time that let-7 is expressed in
he seam cells (Johnson et al., 2003). In contrast, the
ame reporter gene fused to an unregulated control
#UTR was expressed at all stages (Figure 2F; Reinhart
t al., 2000; Slack et al., 2000; Vella et al., 2004; Wight-
an et al., 1993). We found that reporter downregula-
ion directed by the let-60 3#UTR depended on a wild-
ype let-7 gene, since downregulation failed in let-
(n2853) mutants (Figure 2G). Thus, multiple lines of
vidence strongly suggest that let-60 is negatively reg-
lated by let-7. First, the let-60 3#UTR contains multiple
lements complementary to let-7; second, the let-60
#UTR directs downregulation of a reporter gene in a
et-7 dependent manner; third, this downregulation is
eciprocal to let-7 upregulation in the hypodermis; and
inally, let-60 loss of function partially suppresses the
et-7 lethal phenotype.
he let-7 Family Member mir-84 Is Dynamically
xpressed in the Vulval Precursor Cells
et-60/RAS is best understood for its role in vulval de-
elopment (Wang and Sternberg, 2001); however, let-7
as not been reported to be expressed in the vulva. In
. elegans, let-7, mir-48, mir-84, and mir-241 comprise
he let-7 family (Lau et al., 2001; Lim et al., 2003; Rein-
art et al., 2000; Figures S1A and S1B). Our previous
ork demonstrated that a let-7::gfp fusion faithfully re-
apitulates the temporal expression of let-7 and is tem-
orally expressed in seam cell tissues affected in the
et-7 mutant (Johnson et al., 2003). We examined the
xpression pattern of mir-84, the closest let-7 relative,
y fusing 2.2 kilobases (kb) of genomic sequence im-
ediately upstream of the miR-84 encoding sequence
o the green fluorescent protein (gfp) gene. mir-84::gfp
as first observed in the somatic gonad in larval stage
(L1). In L3 animals, strong expression was observed
n uterine cells including the anchor cell (AC), and weak
ynamic expression was observed in the vulval precur-
or cells (VPCs) (Figure 3). VPCs are multipotent ventral
ypodermal cells that generate the vulva during L3 and
ater stages (Sulston and Horvitz, 1977). VPCs adopt
ne of three fates depending on EGF signaling from
he AC (Wang and Sternberg, 2001; Figure 4H). The cell
losest to the AC, P6.p, receives the most LIN-3/EGF
ignal (Katz et al., 1995) and adopts the primary (1°) fate
hrough activation of a RAS/MAPK signal transduction
athway (Beitel et al., 1990; Han et al., 1990; Han and
ternberg, 1990); P5.p and P7.p receive less LIN-3 as
ell as receiving a secondary lateral signal (Sternberg,
988) from P6.p and adopt the secondary (2°) fate;
3.p, P4.p, and P8.p adopt the uninduced tertiary (3°)
ate. mir-84::gfp expression was observed during the
arly to mid L3 stage in all the VPCs except for P6.p,
n which expression was rarely observed (Figures 3A,
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637Figure 1. Potential LCSs in C. elegans let-60/RAS and in Mammalian RAS Genes
(A) C. elegans let-60/RAS mRNA 3#UTR, black arrows indicate sites with similarity between C.e. and C.b. and white arrows indicate nonsimilar
sites. Shown below are predicted duplexes formed by LCSs (top) and miR-84 (bottom). let-7 and miR-84 are so similar that most let-7 sites
are also potential miR-84 sites.
(B–D), H.s. NRAS, KRAS, and HRAS mRNA 3#UTRs have nine, eight, and three potential LCSs, respectively. Black arrows indicate sites
conserved among mammalian species (in most cases human, rat, mouse, hamster, and guinea pig). Shown below are hypothesized duplexes
formed by LCSs (top) and let-7a miRNA (bottom).3P, S1C, and S1D). Subsequent VPC expression in the
mid to late L3 stage was restricted to the daughters
(Pn.px) of P5.p and P7.p with weaker GFP first appear-
ing in the P6.p daughters just before their division into
P6.pxx. Thereafter, equivalent expression was ob-
served in the granddaughters (Pn.pxx) of P5.p, P6.p,
and P7.p (Figures 3E and 3F). We note that mir-84::gfpexpression was observed in all the VPCs except for
P6.p at the stage when their fate in vulval development
is determined by signaling from the AC (Figure 3O;
Ambros, 1999), suggesting that mir-84 could play a role
in vulval cell fate determination. In the L4 stage, GFP
expression was maintained in the AC and other uterine
cells, appeared weakly in hypodermal seam cells (A.
Cell
638Figure 2. let-60 Is Regulated by the let-7 miRNA through Its 3#UTR
(A) Many let-7(n2853); let-60(RNAi) mutant animals do not burst through the vulva at the adult stage at the restrictive temperature (25°C),
while all let-7(n2853) animals do (B).
(C–E) Wild-type animals carrying a reporter gene schematically shown in (C) show robust hypodermal expression of β-galactosidase at the
L1 stage ([D], magnification 400×) but not at the adult stage ([E], composite of multiple images shot at 400×). Asterisk in (E) indicates an
embryo with β-galactosidase activity inside the adult animal, providing an internal control for staining.
(F) Quantitative analysis of the expression pattern from five independent wild-type transgenic lines grown at 20°C. We observed at least 25%
repression in all lines. A nonregulated lin-41 3#UTR missing its LCSs (pFS1031) (Reinhart et al., 2000), tested in duplicate is shown as a control.
(G) Downregulation of the reporter gene expression is lost in let-7(n2853) mutant worms grown at the permissive temperature, 15°C. The
parental (N2) line was tested in triplicate; four isogenic let-7(n2853) mutant lines were tested. Error bars represent standard deviations.Kerscher et al., submitted), and was upregulated to s
hhigher levels in many P5.p–P7.p descendants (Figure
a3G). Interestingly, a second let-7 family member, mir-
a48, was also expressed in non-P6.p VPCs (A. Kerscher
tet al., submitted), suggesting the potential for redun-
pdancy between mir-48 and mir-84 in the VPCs.
s
i
mir-84 Overexpression Causes Vulval 8
and Seam Defects q
We overexpressed miR-84 by generating transgenic 8
animals harboring a multicopy array of a 3.0 kb geno- (
mic DNA fragment that spans from 2.2 kb upstream to o
0.8 kb downstream of the miR-84 encoding sequence s
(called mir-84(+++)). These animals expressed elevated
levels of miR-84 (Figure 4G) and displayed abnormal k
vulval development phenotypes, including protrusion L
and bursting of the vulva (40% of animals, n = 40; Fig- f
ure 4B). They also displayed early division of P6.p and c
precocious vulval invagination in mid to late L3, a heter- b
ochronic phenotype we have not investigated further i
o(Figure 4A). Consistent with mir-84::gfp expression ineam cells, we found that mir-84(+++) animals also ex-
ibited precocious seam cell terminal differentiation
nd alae formation in the L4 stage (Figure 4C), a char-
cteristic seen in precocious developmental timing mu-
ants. In fact, let-7 overexpressing strains also exhibit
recocious seam cell terminal differentiation in the L4
tage (Reinhart et al., 2000). In contrast, animals carry-
ng an array containing a construct identical to mir-
4(+++) except for a 75 nucleotide (nt) deletion of se-
uences encoding the predicted pre-mir-84 (mir-
4(+++)) did not display any vulval or seam defects
data not shown), demonstrating that the phenotypes
bserved in mir-84(+++) are dependent on the miR-84
equence.
We searched for LCSs in the 3#UTRs of all genes
nown to play a role in vulval development (Table S1).
CSs have the potential to bind all members of the let-7
amily, including mir-84. Approximately 11 vulval genes
ontained at least one LCS (Table S1), raising the possi-
ility that the let-7 family may regulate multiple genes
n the vulva. In this analysis though, let-60/RAS stood
ut due to the high number of LCS sites.
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639Figure 3. mir-84::gfp and gfp60 Are Expressed Reciprocally in the Pn.p Cells
(A, C, E, and G) In L3, mir-84::gfp is expressed in all Pn.p cells except P6.p during the time of vulval fate determination ([O], bracket) and is
upregulated in P6.pxx cells thereafter (mL3, lL3, and vlL3 are mid, late, and very late L3, respectively).
(I, K, and M) gfp60, a fusion of gfp to the let-60 3#UTR, driven by the lin-31 promoter, is expressed in all Pn.p cells at late L2 and early L3 (I
and J), is then restricted to P6.p (K and L) during vulval fate determination, and thereafter is expressed strongly in P6.px cells and weakly in
P5.px and P7.px cells (M and N). Images on right are Nomarski images of animals on left.
(O) gfp60 and mir-84::gfp expression schematic from L2 Pn.p to mid L3 Pn.px.
(P–R), Quantification of expression data shown in (A–N). gfp54 is a fusion of gfp to the unc-54 3#UTR, driven by the lin-31 promoter.
Error bars represent standard deviations. See Experimental Procedures for details.mir-84 Overexpression Partially Suppresses
let-60/RAS Gain of Function Phenotypes
let-60/RAS is active in P6.p following a lin-3 EGF signal
from the anchor cell that activates a MAPK signal trans-
duction cascade transforming P6.p to the 1° vulval fate
(Han and Sternberg, 1990). Since mir-84 is expressed
in all VPCs except P6.p, we examined the possibility
that mir-84 negatively regulates expression of let-60/RAS in cells not destined to adopt the 1° fate. Activa-
ting mutations in let-60/RAS cause multiple VPCs (in-
cluding the non-P6.p VPCs) to adopt 1° or 2° fates lead-
ing to a multivulva (Muv) phenotype (Han et al., 1990).
We found that overexpression of mir-84 partially sup-
pressed the Muv phenotype of let-60(gf) mutations. In
our study 41% (n = 51) of let-60(ga89) (Eisenmann and
Kim, 1997) animals displayed a Muv phenotype, while
Cell
640Figure 4. Overexpression of mir-84
In L3, mir-84(+++) animals display precocious division of P6.p and precocious vulval invagination (A). In L4, mir-84(+++) results in an everted
and protruding vulva (B) and precocious alae formation (C).
(D–F), Overexpressing mir-84 in let-60(n1046gf) animals partially suppresses the let-60(gf) Muv phenotype, whereas an empty vector control
and mir-84(+++) do not.
(G), Northern blot showing that mir-84(+++) animals express more miR-84, compared to wild-type animals. 5.8S RNA is shown as a loading
control.
(H), Model of miR-84 modulation of let-60/RAS during vulval morphogenesis. During vulval cell fate specification a LIN-3/EGF signal emanating
from the anchor cell is received by the LET-23/EGFR on the P5.p, P6.p and P7.p cells. The P6.p receives the most LIN-3 and activates a RAS/
MAPK signal transduction pathway to adopt the 1° fate. P5.p and P7.p receive less LIN-3 and also receive a second, lateral signal (involving
LIN-12/Notch) from the 1° cell that induces them to the 2° fate. We propose that miR-84 is expressed in the non-1° lineage to reduce
expression of LET-60/RAS in these cells.only 13% (n = 168) did so when also overexpressing g
tmir-84 from a multicopy array (p << 0.0001, chi-square
test). The same suppression was observed with a se- a
Vcond let-60(gf) allele, let-60(n1046) (Han et al., 1990):
77% (n = 39) of let-60(n1046) animals displayed a Muv I
iphenotype (Figure 4E), while only 50% (n = 113) did so
when also overexpressing mir-84 (Figure 4D; p << s
u0.0001, chi-square test). let-60(n1046) animals dis-
played an average of 1.54 pseudovulvae per animal P
compared to an average of 0.66 pseudovulvae per let- s
60(n1046) animal overexpressing mir-84. For both let- u
60(gf) alleles, animals exhibiting low mosaicism for the a
myo-3::gfp coinjection marker were completely sup- a
pressed (data not shown), suggesting that the partial m
suppression was likely due to mosaicism of the d
transgeneic array. Neither an empty vector control
(TOPO) (n = 111; p = 0.1435, chi-square test) nor the u
mir-84(+++) array (n = 129; Figure 4F), suppressed the w
Muv phenotype of let-60(n1046). For all let-60(gf) ex- 6
periments, three independent lines behaved similarly s
(Figure S3C). f
s
tThe let-60/RAS 3UTR Confines Expression to P6.p
The promoter of let-60/RAS drives reporter expression r
lin all VPCs (Dent and Han, 1998). However, the trans-enic reporters used in this earlier work did not include
he let-60 3#UTR. We fused GFP to the let-60 3#UTR
nd drove GFP expression in all the VPCs using the
PC-specific lin-31 (Tan et al., 1998) promoter (gfp60).
n the late L2 and early L3 stages, GFP was expressed
n all the Pn.p cells (Figure 3I), but by mid to late L3
tages, GFP was largely restricted to the P6.p cell (Fig-
res 3K and 3Q), with some expression in the P5.p and
7.p cell descendants (Figure 3M). A similar fusion con-
truct in which the let-60 3#UTR was replaced by the
nregulated unc-54 3#UTR showed GFP expression in
ll Pn.p cells (Figure 3R). Since the lin-31 promoter is
ctive in all Pn.p cells (Tan et al., 1998), this result de-
onstrates that the let-60/RAS 3#UTR is sufficient to
ownregulate a reporter gene in the non-P6.p cells.
We replaced the let-60 3#UTR with the unregulated
nc-54 3#UTR in a let-60 genomic DNA fragment. While
e could generate viable lines using a let-60::let-
0(+)::let-60 3#UTR construct at 10 ng/l (data not
hown), we were unable to generate viable trans-
ormants using this let-60::let-60(+)::unc-54 3#UTR con-
truct, even at 0.1 ng/l. We did not try lower concen-
rations of DNA, but our result suggests that the
emoval of the let-60 3#UTR may severely overexpress
et-60 and cause lethality.
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Previous work has demonstrated that VPCs are sensi-
tive to the levels of let-60/RAS (Beitel et al., 1990; Han
and Sternberg, 1990). Animals carrying extra copies of
the wild-type let-60/RAS gene display a Muv pheno-
type, where non-P6.p VPCs can adopt the 1° fate. Our
data strongly suggest that mir-84 negatively regulates
let-60 in non-P6.p VPCs. First,mir-84 is complementary
to multiple sites in the let-60 3#UTR. Second, mir-84 is
expressed in a reciprocal manner to let-60 in the VPCs.
miR-84 is largely absent from P6.p, at the same time as
the let-60 3#UTR confines GFP expression mainly to the
P6.p cell lineage. Finally, mir-84 overexpression par-
tially suppresses the effects of activating mutations in
the let-60 gene. We propose that mir-84 modulates the
expression of let-60/RAS in non-P6.p VPCs to reduce
flux through the RAS/MAPK signaling pathway and
hence decrease the likelihood that these cells will also
adopt the 1° fate (Figure 4H). However, mir-84 is clearly
not the only regulator of let-60/RAS in non-P6.p cells:
daf-12(rh61) mutants do not express mir-84 in any VPC
(n = 60 animals), and yet daf-12(rh61) animals do not
display a Muv phenotype (data not shown). Other
known factors, e.g., synmuv genes (Berset et al., 2001;
Ceol and Horvitz, 2004; Hopper et al., 2000; Lee et al.,
1994; Wang and Sternberg, 2001; Yoo et al., 2004; Yoon
et al., 1995) or unknown factors may also regulate let-
60/RAS signaling in these cells.
Our combined results provide strong evidence that
let-7 and mir-84 regulate let-60/RAS expression through
its 3#UTR in seam and vulval cells, cells in which they
are all naturally expressed. Given that the 3#UTR of let-
60/RAS contains multiple let-7/mir-84 complementary
sites, we propose that this regulation is direct.
let-7 Complementary Sites in Human RAS 3UTRs
Numerous miRNAs are altered in human cancers (Calin
et al., 2002; Calin et al., 2004; Michael et al., 2003; Tam
et al., 2002) and three of the best understood miRNAs,
lin-4 (Lee et al., 1993), let-7 (Reinhart et al., 2000), and
bantam (Brennecke et al., 2003), all regulate cell prolif-
eration and differentiation. The closest human homo-
logs of let-7 andmir-84 are the H.s. let-7 family miRNAs
(Lagos-Quintana et al., 2002; Pasquinelli et al., 2000).
let-60/RAS is the C. elegans ortholog of human HRAS,
KRAS, and NRAS (Figures S3A and S3B), which are
commonly mutated in human cancer (Malumbres and
Barbacid, 2003), including lung cancer. We found that
all three human RAS 3#UTRs contain multiple putative
let-7 complementary sites with features of validated
C. elegans LCSs (Figures 1B, 1C, and 1D). Many of
these are conserved in rodents, amphibians, and fish
(Figure S4), suggesting functional relevance. The pres-
ence of putative LCSs in human RAS 3#UTRs suggests
that mammalian let-7 family members may regulate hu-
man RAS in a manner similar to the way let-7 and mir-
84 regulate let-60/RAS in C. elegans.
Human RAS Expression Is regulated
by let-7 in Cell Culture
Microarray analysis on six different cell lines revealed
that HepG2 cells express let-7 at levels too low to de-tect by microarray analysis (data not shown). We trans-
fected HepG2 cells with a double-stranded (ds) RNA
that mimics the let-7a precursor. A similar approach has
been used to study other miRNAs in mammalian cells
(Chen et al., 2004; Lewis et al., 2003). Consistent with
the prediction that RAS expression is negatively regu-
lated by let-7, immunofluorescence with a RAS-specific
antibody revealed that the protein is reduced by ap-
proximately 70% in HepG2 cells transfected with exog-
enous let-7a miRNA relative to the same cells trans-
fected with a negative control miRNA (Figures 5A and
5B). The protein expression levels of GAPDH and
p21CIP1 were largely unaffected by the transfected let-
7a and negative control pre-miRNAs (Figures S5A and
S5B), indicating that let-7a regulation is specific to
RAS. To confirm that the RAS antibody is specific to
RAS protein in the transfected cells, HepG2 cells were
also independently transfected with two exactly com-
plementary siRNAs targeting independent regions of
NRAS. Both siRNAs reduced cell fluorescence by more
than 60% as compared to negative control siRNA-
transfected cells (Figures S5C and S5D).
We predicted that cells expressing native let-7 may
express less RAS protein and that inhibition of let-7
may lead to derepression of RAS expression. To test
this, we transfected HeLa cells, which express endoge-
nous let-7 (Lagos-Quintana et al., 2001; Lim et al.,
2003), with antisense molecules designed to inhibit the
activity of let-7 (Hutvágner et al., 2004; Meister et al.,
2004). Reducing the activity of let-7 in HeLa cells re-
sulted in an w70% increase in RAS protein levels (Fig-
ures 5C and 5D). These results, combined with the re-
ciprocal experiment using pre-let-7 miRNAs discussed
above, strongly suggest that let-7 negatively regulates
the expression of RAS in human cells.
We fused the 3#UTR of human NRAS and KRAS to a
luciferase reporter gene and transfected these con-
structs along with transfection controls into HeLa cells.
NRAS contains two naturally occurring 3#UTRs that uti-
lize alternative polyadenylylation and cleavage sites,
such that one of the 3#UTRs is 2.5 kb longer than the
other. We found that while the long NRAS 3#UTR
strongly repressed reporter expression compared to an
unregulated control 3#UTR (Figures 6A and 6B), the
short NRAS 3#UTR led to only slight, but reproducible,
repression of the reporter. The short 3#UTR contains
four LCSs, while the long form contains nine LCSs. The
KRAS 3#UTR also repressed the luciferase reporter
(Figures 6A and 6B), while HRAS was not tested. Our
results demonstrate that the 3#UTRs of NRAS and
KRAS contain regulatory information, sufficient to down-
regulate the reporter. Little is known about the exact
characteristics that convey functionality to a miRNA
complementary site, and future work may reveal the dif-
ferences between the NRAS and KRAS 3#UTRs.
As with the endogenous RAS experiments described
above, we performed the reciprocal experiment wherein
we cotranfected HeLa cells with the RAS 3# UTR repor-
ter constructs and the let-7a antisense inhibitor mole-
cule (or a control scrambled molecule). Cells trans-
fected with the let-7a inhibitor relieved repression
exerted on the reporter relative to the control transfec-
tions (Figure 6C). Since we observe a loss in the extent
Cell
642Figure 5. The Presence of let-7 Influences the Expression of RAS in Human Cells
(A) HepG2 cells were transfected with 10 and 30 nM of a let-7 or negative control precursor miRNA. Immunofluorescence using an antibody
specific to NRAS, VRAS, and KRAS revealed that the let-7 transfected cells have much lower levels of the RAS proteins.
(B) Quantification of the RAS antibody fluorescence from replicates of the transfections shown in (A).
(C) HeLa cells were transfected with 100 nM let-7 inhibitor or negative control inhibitor. RAS immunofluorescence revealed that cells trans-
fected with the let-7 inhibitor have increased levels of the RAS proteins relative to the negative control transfected cells.
(D) Quantification of the RAS antibody fluorescence from replicates of the transfections shown in (C).of downregulation when let-7 is inhibited, these results f
estrongly suggest that let-7 regulates NRAS and KRAS
in human cells through their 3#UTRs. o
c
mlet-7, RAS, and Lung Cancer
Like let-60/ras, human RAS is dose sensitive, since s
2overexpression of RAS results in oncogenic trans-ormation of human cells (McKay et al., 1986; Pulciani
t al., 1985). It is plausible that loss of miRNA control
f RAS could also lead to overexpression of RAS and
ontribute to human cancer. Indeed, recent work has
apped let-7 family members to human chromosomal
ites implicated in a variety of cancers (Calin et al.,
004). In particular let-7a-2, let-7c and let-7g have been
let-7 MicroRNAs Regulate Expression of RAS
643Figure 6. The 3#UTRs of NRAS and KRAS En-
able let-7 Regulation
(A) Cartoon showing the NRAS short (NRAS
s) NRAS long (NRAS l) and KRAS 3#UTRs.
Arrows indicate LCSs as described in Figure
1. The blackened areas indicate the se-
quence cloned behind the reporter.
(B) Relative repression of firefly luciferase
expression standardized to a transfection
control, renilla luciferase. pGL3-Cont is the
empty vector.
(C) Induction of firefly luciferase expression
when reporter plasmids with 3#UTR domains
corresponding to KRAS and NRAS are co-
transfected with an inhibitor of let-7, relative
to a control inhibitor.linked to small chromosomal intervals that are deleted
in lung cancers (Calin et al., 2004), a cancer type in
which RAS misregulation is known to be a key onco-
genic event (Ahrendt et al., 2001; Johnson et al., 2001).
We utilized a miRNA microarray to examine expres-
sion levels of members of the let-7 gene family in tissue
from 21 different cancer patients, including 12 lung
cancer patients with squamous cell carcinomas (stage
IB or IIA). We found that the let-7miRNAs were reduced
in expression in a number of the tumors relative to the
normal adjacent tissue (NAT) samples from the same
patients (Figure 7A). Interestingly, we found that let-7
was expressed at lower levels in all of the lung tumor
tissues (Figure 7) but only sporadically in other tumor
types. A similar finding was independently discovered
(Takamizawa et al., 2004). On average, let-7 was ex-
pressed in lung tumors at less than 50% of what it was
expressed in the associated normal lung samples (Fig-
ure 7A). We used Northern analysis to measure let-7c
in the tumor and NAT samples for the two patients from
which we purified enough RNA (samples represented
by the first and fifth lung cancer bars in Figure 7A). Con-
sistent with the microarray results, Northern analysis
verified that the expression of let-7c was 65% lower in
the tumor of patient 1 and 25% lower in the tumor of
patient 5 (Figure 7B). Seven of eight examined samples
also had on average 30% less let-7g expression in the
tumor tissue (Figure S6). The miRNA arrays used to
compare the lung tumors and NAT included probes for
167 total miRNAs; the expression of the vast majority
of these were unchanged in the lung tumors (J.S. andD.B., unpublished data) indicating that let-7 might be
important in lung cancer. In theory, downregulation of
let-7 could result in upregulation of RAS and thus in-
duce or accentuate oncogenesis.
To test this hypothesis, we isolated total RNA and
total protein from the tumor and normal adjacent tis-
sues of three new lung cancer patients with squamous
cell carcinoma. The RNA samples were split and half
was used for Northern analysis to measure let-7c and
U6 snRNA. The other halves of the RNA samples were
used for real-time PCR to measure the NRAS mRNA,
18S rRNA, and B-actin mRNA. The protein samples
were used for Western analysis to assess RAS and
GAPDH protein levels. As seen in Figure 7C, RAS pro-
tein was present in the tumors at levels at least 10-fold
higher than in the normal adjacent samples from the
same patients. Consistent with the miRNA array results
for other lung cancer samples, all three lung tumor
samples had 4- to 8-fold lower levels of let-7 than did
the corresponding NAT samples. Interestingly, the first
and third lung cancer samples had similar levels of
NRAS mRNA in both the tumor and NAT while the
second sample pair had significantly higher levels of
NRAS mRNA in the tumor sample. In our limited analy-
sis, RAS protein levels correlate poorly with NRAS
mRNA levels but very well with let-7 levels, suggesting
that the expression of the oncogene is significantly in-
fluenced at the level of translation, consistent with the
known mechanism of let-7 in invertebrates.
The reciprocal expression pattern between let-7 and
RAS in cancer cells closely resembles what we saw
Cell
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(A) Expression of let-7 in 21 breast, colon, and lung tumors relative to associated NAT. Fluorescently labeled miRNA was hybridized to
microarrays that included probes specific to let-7a and let-7c. Fluorescence intensities for the tumor and NAT were normalized by total
fluorescence signal for all elements, and the relative average signal from the let-7 probes in the tumor and normal adjacent samples are
expressed as log ratios. Note, let-7a and let-7c had similar profiles, suggesting crosshybridization between the two closely related miRNAs.
(B) Confirmation of differential let-7c expression in tumor versus normal adjacent samples. The Northern blot was assayed sequentially with
radio-labeled probes specific to let-7c and 5S rRNA. The relative expression of let-7c in NAT versus tumor tissue, normalized to the 5S signal,
is shown in patients corresponding to lung sample 1 and 5 from (A).
(C) Correlation between RAS protein and let-7c expression in tumor and normal adjacent tissue samples from three lung squamous cell
carcinomas. GAPDH and RAS proteins were measured from crude extracts of tumor and normal adjacent tissues using Western analysis.
The two proteins were assessed simultaneously by mixing the antibodies used for detection. The small RNA Northern blot was assayed
sequentially with radio-labeled probes specific to let-7c and U6 snRNA. NRAS mRNA in the tumor and normal adjacent tissues samples was
measured by real-time PCR. The real-time data were normalized based on the real-time PCR detection of 18S rRNA in the various samples.
The relative expression of NRAS in the normal adjacent tissues was taken to be 100%, and the Ct value of NRAS in the tumor samples was
used to assign the relative expression of NRAS in the tumor samples.with let-7 and RAS in C. elegans and in our human tis- o
Rsue culture experiments. The correlation between re-
duced let-7 expression and increased RAS protein ex- o
opression in the lung tumor samples suggests that oner more members of the let-7 gene family regulates
AS expression in vivo and that the level of expression
f the miRNA might be an important factor in limiting
r contributing to oncogenesis.
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Our work reveals that the let-7 miRNA family negatively
regulates RAS in two different C. elegans tissues and
in two different human cell lines. Strikingly, let-7 is ex-
pressed in normal adult lung tissue (this work; Pas-
quinelli et al., 2000) but is poorly expressed in lung can-
cer cell lines and lung cancer tissue (this work; Takami-
zawa et al., 2004). The expression of let-7 inversely
correlates with expression of RAS protein in lung can-
cer tissues, suggesting a possible causal relationship.
In addition, overexpression of let-7 inhibited growth of
a lung cancer cell line in vitro (Takamizawa et al., 2004),
suggesting a causal relationship between let-7 and cell
growth in these cells. The combined observations that
let-7 expression is reduced in lung tumors, that several
let-7 genes map to genomic regions that are often de-
leted in lung cancer patients, that overexpression of
let-7 can inhibit lung tumor cell line growth, that the
expression of the RAS oncogene is regulated by let-7,
and that RAS is significantly overexpressed in lung tu-
mor samples strongly implicate let-7 as a tumor sup-
pressor in lung tissue and suggests a possible mech-
anism.
Experimental Procedures
Plasmid Constructs
See Supplemental Experimental Procedures for details of plasmid
construction.
C. elegans and Transgenic Reporter Analysis
All animal experiments were performed at room temperature or
20°C unless stated otherwise. All experimental plasmids were in-
jected in animals at 50–100 ng/l. Two different markers, rol-6 (100
ng/l) and myo-3::gfp (50 ng/l), were separately coinjected with
PSJo84. myo-3::gfp (50 ng/l) was coinjected with o8484, and
myo-2::gfp (5 ng/l) was coinjected with GFP60 and GFP54. These
animals are mosaic for the transgenes. To compare expression be-
tween individual lines, the percent expression of GFP in each of the
Pn.p cells was normalized relative to the expression of the highest
expressing Pn.p cell and represented as a fraction of the highest
expresser for each individual line of animals. For each construct,
the average of the lines was calculated along with the standard
deviation for each construct represented as error bars (mir-84::gfp
n = 239, gfp60 n = 42 and gfp54 n = 40). For the mir-84(+++) analy-
sis, animals were examined using DIC optics to score seam cell
and vulval anatomy. LacZ reporter analysis was as described (Vella
et al., 2004). The lin-41 3UTR missing its LCSs (pFS1031) was used
as a control (Reinhart et al., 2000). RNAi methods were standard
feeding procedures using synchronized L1s (Timmons et al., 2001).
All RNAi experiments were done in parallel to an empty vector
(L4440) feeding control. See Supplemental Experimental Proce-
dures for details on the let-60; let-7 double mutant cross.
let-7/RAS Association in Mammalian Cells
HeLa S3 cells grown in D-MEM (GIBCO) supplemented with 10%
fetal bovine serum (GIBCO) were cotransfected in 12-well plates
using Lipofectamine 2000 (Invitrogen) according to the manufactur-
er’s protocol using 1.0 g/well of Pp-luc-expressing plasmid
(pGL3-Control from Promega, pGL3-NRAS S pGL3-NRAS L and
pGL3-KRAS) and 0.1 g/well of Rr-luc-expressing plasmid (pRL-TK
from Promega). 24 hr posttransfection, the cells were harvested
and assayed using the Dual Luciferase assay as described by the
manufacturer (Promega). HeLa cells grown as above were trans-
fected in 24-well plates with 30 pmol of Anti-miR let-7 or negative
control 1 inhibitors (Ambion) using Lipofectamine 2000. Three daysposttransfection, RAS expression was monitored by immunofluo-
rescence using an FITC conjugated primary antibody against RAS
protein (US Biological). The resulting fluorescent signal was ana-
lyzed using the appropriate filter set and was quantified using Meta-
Morph software. We typically measured the fluorescence intensity
of 150–300 cells in one or a few viewing areas. The experiments
with both the precursors and the inhibitors were performed three
times. The photos represent single viewing fields from one of the
experiments and are representative of the triplicate experiment.
Identically grown HeLa cells were cotransfected in 24-well plates
using Lipofectamine 2000 (Invitrogen) according to the manufactur-
er’s protocol using 200 ng /well of Pp-luc-expressing plasmid
(pGL3-Control from Promega, pGL3-NRAS S pGL3-NRAS L and
pGL3-KRAS). 48 hr posttransfection, the cells were harvested and
assayed using the Luciferase assay as described by the manufac-
turer (Promega).
HepG2 cells grown in D-MEM (GIBCO) supplemented with 10%
fetal bovine serum (GIBCO) were transfected with 15 or 5 pmol of
Pre-miR Let-7c or negative control 1 Precursor miRNAs (Ambion)
in 24-well plates using siPort Neo-FX (Ambion) according to the
manufacturer’s protocol. Three days posttransfection, RAS expres-
sion was monitored by immunofluorescence as described above.
MiRNA Microarray Analysis
Total RNA from tumor and NAT samples from three breast cancer,
six colon cancer, and twelve lung cancer patients was isolated
using the mirVana RNA Isolation Kit (Ambion). Twenty micrograms
of each total RNA sample was fractionated by polyacrylamide gel
electrophoresis (PAGE) using a 15% denaturing polyacrylamide gel,
and the miRNA fractions for each sample were recovered. The
miRNAs from all of the samples were subjected to a poly(A) poly-
merase reaction wherein amine modified uridines were incorpo-
rated as part of w40 nt long tails (Ambion). The tailed tumor sam-
ples were fluorescently labeled using an amine-reactive Cy3
(Amersham), and the normal adjacent tissue samples were labeled
with Cy5 (Amersham). The fluorescently labeled miRNAs were puri-
fied by glass-fiber filter binding and elution (Ambion), and the tumor
and normal adjacent tissue samples from the same patient were
mixed. Each sample mixture was hybridized for 14 hr with slides
upon which 167 miRNA probes were arrayed. The microarrays were
washed 3 × 2 min (min) in 2× SSC and scanned using a GenePix
4000B (Axon). Fluorescence intensities for the Cy3- and Cy5-
labeled samples for each element were normalized by total Cy3
and Cy5 signal on the arrays. The normalized signal intensity for
each element was compared between the tumor and NAT samples
from each pair of patient samples and expressed as a log ratio of
the tumor to normal adjacent sample.
Northern Analysis
mir-84 Northerns were performed as described (Johnson et al.,
2003). For human tissues, 1 g of total RNA from the tumor and
normal adjacent tissues of patients 1 and 5 (Figure 7A) were frac-
tionated by PAGE using a 15% denaturing polyacrylamide gel. The
RNA was transferred to a positively charged nylon membrane by
electroblotting at 200 mA in 0.5× TBE for 2 hr. The Northern blot
was dried and then incubated overnight in 10 ml of ULTRAhyb-
Oligo (Ambion) with 107 cpm of a radio-labeled transcript comple-
mentary to let-7c. The blot was washed 3 × 10 min at room temper-
ature in 2× SSC, 0.5% SDS and then 1 × 15 min at 42°C in 2× SSC,
0.5% SDS. Overnight phosphorimaging using the Storm system
(Amersham) revealed let-7c. The process was repeated using a ra-
dio-labeled probe for 5S rRNA.
Lung Tumor Protein/Northern/mRNA Analysis
Total RNA and protein were isolated from tumor and normal adja-
cent tissue samples from three lung cancer patients using the mir-
Vana PARIS Kit (Ambion). let-7 miRNA and U6 snRNA were mea-
sured using the Northern procedure described above. NRAS and
B-actin mRNA as well as 18S rRNA were quantified by real-time
RT-PCR using primers specific to each of the target RNAs. RAS
and GAPDH protein were measured by Western analysis using the
Cell
646RAS antibody described above and an antibody for GAPDH C
m(Ambion).
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Supplemental Data include six figures, one table, and Supplemen- 1
tal Experimental Procedures and can be found with this article on- E
line at http://www.cell.com/cgi/content/full/120/5/635/DC1/. o
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Accession Numbers
The following sequences were searched for 3#UTR LCSs: Hs KRAS
(GenBank M54968), Hs HRAS (NM176795), Hs NRAS (BC005219).
NRAS is known to exist as a 2 kb and a 4.3 kb form. BC005219
represents the short form with an 1151 nt polyadenylated 3#UTR.
We sequenced two human EST clones (GenBank BU177671 and
BG388501) to obtain additional NRAS 3#UTR sequence. This re-
vealed that the NRAS 3#UTR exists in a 3642 nt polyadenylated
3#UTR version, utilizing an alternative polyadenylation and cleav-
age site, 2491 nt downstream of the first. This presumably corres-
ponds to the long NRAS form. The sequences were deposited with
accession numbers AY941100 and AY941101.
